Article
MDM4 is a rational target for treating breast cancers with mutant p53.
The Journal of pathology - 1 Apr 2017
Miranda Panimaya Jeffreena, Buckley Daniel, Raghu Dinesh, Pang Jia-Min B, Takano Elena A, Vijayakumaran Reshma, Teunisse Amina Fas, Posner Atara, Procter Tahlia, Herold Marco J, Gamell Cristina, Marine Jean-Christophe, Fox Stephen B, Jochemsen Aart, Haupt Sue, Haupt Ygal
Abstract excerpt
Mutation of the key tumour suppressor p53 defines a transition in the progression towards aggressive and metastatic breast cancer (BC) with the poorest outcome. Specifically, the p53 mutation frequency exceeds 50% in triple-negative BC. Key regulators of mutant p53 that facilitate its oncogenic functions are potential therapeutic targets. We report here that the MDM4 protein is frequently abundant in the context...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.